Apr 4 2013
NorDx, (Northern Diagnostic Laboratories), the largest reference laboratory in the state of Maine and a member of MaineHealth, today announces the acquisition of Sysmex® XN-Series Automated Hematology Analyzers. NorDx and MaineHealth are the first clinical laboratories in the country to acquire the new Sysmex XN-Series hematology analyzers.
The analyzers enhance the clinical laboratories' turnaround times for patient blood counts results, thereby enabling physicians and other healthcare professionals to treat patients sooner, according to Stan Schofield , President of NorDx, Senior Vice President of MaineHealth. The analyzers also offer unique advantages for testing both normal and abnormal hematology samples. "Our clinical laboratories will now be able to further improve differentiation of anemia types, better monitor bone marrow transplants, better aid in the diagnoses of leukemia and other diseases with immature cells in the circulating blood and help improve the diagnosis of possible bleeding disorders," added Schofield. NorDx is accredited by the College of American Pathologists and offers a full range of laboratory services to multiple hospital sites, physician practices, and long-term care facilities in the tri-state region of Maine, New Hampshire and Vermont.
"As a member of one of the nation's top 100 integrated delivery networks, we understand that our clinical excellence starts with the core technology and clinical utility of our laboratory's instrumentation and ends with diagnosis, treatment and improved quality of life for the patient," said Schofield. "The Sysmex® XN-Series is a powerful new technology platform that sets an entirely new standard of testing sophistication and capacity. No doubt, these new analyzers have broad implications for the health and vitality of our community considering much of a patient's medical record is comprised of laboratory results," added Schofield.
The acquisition of the Sysmex XN-Series automated hematology analyzers also help NorDx and MaineHealth address cost and labor pressures, including projected shortage of medical technologists, increasing workload demands and the testing complexity of an aging population.